# Biogen: Phase 3 study closed enrollment, 152 enrolled (Multiple Sclerosis, Relapsing-Remitting)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Biogen |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis |
| NCT ID | NCT03958877 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention types | drug |
| Target enrollment | 152 |
| Site countries | United States, Argentina, Australia, Belgium, Bulgaria, Croatia, Czechia, France, Germany, Greece, Hungary, Israel |
| Posted | 2019-05-22 |
| Planned start | 2019-10-18 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-24 |
| Last update posted | 2026-09-24 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 152 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03958877). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.